Biotechnology company developing adoptive cell therapy for the treatment of cancer.
Iovance Biotherapeutics, Inc. is a dynamic biotechnology company in the clinical-stage, specializing in the development and commercialization of cutting-edge cancer immunotherapy products. The company's mission centers on leveraging the innate power of a patient's immune system to combat and eradicate cancer cells effectively. At present, Iovance Biotherapeutics is actively advancing six phase 2 clinical studies, notably including lifileucel in trials such as C-144-01 for metastatic melanoma, C-145-04 for recurrent cervical cancer, and C-145-03 for head and neck squamous cell carcinoma.
Through strategic collaborations and licensing agreements with prestigious institutions like H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Universite de Montreal, Cellectis S.A., and Novartis Pharma AG, Iovance Biotherapeutics enhances its research capabilities and expands its therapeutic reach. Originally known as Lion Biotechnologies, Inc., the company rebranded as Iovance Biotherapeutics, Inc. in June 2017, reflecting its evolution and commitment to pioneering advancements in cancer treatment.
Founded in 2007 and headquartered in San Carlos, California, Iovance Biotherapeutics continues to push the boundaries of medical innovation. Its comprehensive approach to cancer immunotherapy focuses not only on developing groundbreaking treatments but also on fostering strategic partnerships to accelerate the availability of these therapies to patients globally.
Driven by a passion for scientific excellence and patient-centric care, Iovance Biotherapeutics remains dedicated to transforming the landscape of cancer treatment. With a robust pipeline and a collaborative network of research partnerships, the company is poised to lead advancements in immunotherapy, aiming to provide hope and improved outcomes for individuals battling cancer.